Calidi Biotherapeutics, Inc.

CLDI

Exchange: NYSE
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001855485

SEC filings (opens in a new tab)

No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.

Other share classesCLDWW

Q4 2023 vs. Q3 2023

How the institutions holding Calidi Biotherapeutics, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023 All holders in Q3 2023

13F holders of CLDI: Q3 2023 compared with Q4 2023
Measure	Q3 2023	Q4 2023	Change
Holders	13	25	+12
Shares	1.07M	1.90M	+828.7K (+77.2%)
Value	$3.54M	$2.83M	−$714.4K (−20.2%)

New holders (15)

Institutions that held Calidi Biotherapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to CLDI in Q4 2023
Institution	Shares	Value	% of portfolio
Cable Car Capital LLC	538,860	$813.7K	0.85%
Millennium Management LLC	102,317	$154.5K	0.00%
Geode Capital Management, LLC	102,238	$154.4K	0.00%
Governors Lane LP	94,697	$143.0K	0.04%
Magnetar Financial LLC	63,132	$75.6K	0.00%
Pegasus Partners Ltd.	37,812	$57.1K	0.01%
Morgan Stanley	19,187	$29.0K	0.00%
Renaissance Technologies LLC	17,079	$26.0K	0.00%
Axxcess Wealth Management, LLC	13,190	$19.9K	0.00%
Vanguard Group Inc	12,448	$18.8K	0.00%
Pure Financial Advisors, Inc.	11,892	$18.0K	0.00%
Qube Research & Technologies Ltd	2,752	$4.16K	0.00%
BlackRock Inc.	2,588	$3.91K	0.00%
Wells Fargo & Company	138	$208	0.00%
Tower Research Capital LLC (TRC)	1	$2	0.00%

Sold out (3)

Institutions that held Calidi Biotherapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of CLDI in Q4 2023
Institution	Shares, Q3 2023	Value, Q3 2023
Highbridge Capital Management LLC	125,000	$415.6K
Kayne Anderson Rudnick Investment Management LLC	9,174	$30.5K
Bank of America Corp	100	$332